The FDA has approved zanubrutinib for the treatment of Waldenstrom’s macroglobulinemia

September 2021: For adult patients with Waldenström’s macroglobulinemia, the FDA has approved zanubrutinib (Brukinsa, BeiGene) (WM).

In ASPEN (NCT03053440), zanubrutinib was compared to ibrutinib in patients with MYD88 L265P mutation (MYD88MUT) WM. Cohort 1 (n=201) patients were randomly assigned to receive either zanubrutinib 160 mg twice day or ibrutinib 420 mg once daily until disease progression or intolerable toxicity. Patients in Cohort 2 were given zanubrutinib 160 mg twice daily and were either MYD88 wildtype (MYD88WT) or MYD88 mutation unknown WM (n=26 and 2, respectively).

Response rate, defined as a partial response (PR) or better as judged by an independent review committee using conventional consensus response criteria from the International Workshop on Waldenström’s Macroglobulinemia-6, was the primary efficacy outcome used to support approval. The length of reaction was another efficacy outcome metric (DOR).

The zanubrutinib arms were approved based on a non-comparative evaluation of response and DOR. The zanubrutinib arm had a response rate of 77.5 percent (95 percent confidence interval: 68.1,85.1). The zanubrutinib group had a 94.4 percent event-free DOR at 12 months (95 percent CI: 85.8, 97.9). Response (CR+VGPR+PR) was detected in 50% of the Cohort 2 participants, according to IRC (13 out of 26 response evaluable patients; 95 percent CI: 29.9, 70.1).

Neutrophil count decreased, upper respiratory tract infection, platelet count decreased, rash, haemorrhage, musculoskeletal pain, haemoglobin decreased, bruising, diarrhoea, pneumonia, and cough are the most common adverse reactions, including laboratory abnormalities, reported with zanubrutinib (20 percent).

The recommended dose of zanubrutinib is 160 mg twice a day or 320 mg once a day.

Nishant Mittal (PhD)

+ postsBio ⮌

Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. His career is marked by significant contributions to stem cell biology, developmental biology, and innovative research techniques.

Research Highlights

Dr. Mittal's research has focused on several key areas:

1) Cardiovascular Development and Regeneration: He studied coronary vessel development and regeneration using zebrafish models1.

2) Cancer Biology: At Dartmouth College, he developed zebrafish models for studying tumor heterogeneity and clonal evolution in pancreatic cancer.
3) Developmental Biology: His doctoral work at Keio University involved identifying and characterizing medaka fish mutants with cardiovascular defects.

4) Stem Cell Research: He investigated the effects of folic acid on mouse embryonic stem cells and worked on cryopreservation techniques for hematopoietic stem cells.

Publications and Presentations

Dr. Mittal has authored several peer-reviewed publications in reputable journals such as Scientific Reports, Cardiovascular Research, and Disease Models & Mechanisms1. He has also presented his research at numerous international conferences, including the Stanford-Weill Cornell Cardiovascular Research Symposium and the Weinstein Cardiovascular Development Conference.

In summary, Dr. Nishant Mittal is a dedicated and accomplished researcher with a strong track record in cardiovascular and cancer biology, demonstrating expertise in various model systems and a commitment to advancing scientific knowledge through innovative research approaches.

• Nishant Mittal (PhD)

  https://cancerfax.com/author/nishantm/

  Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
• Nishant Mittal (PhD)

  https://cancerfax.com/author/nishantm/

  Mirdametinib is approved by the USFDA for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
• Nishant Mittal (PhD)

  https://cancerfax.com/author/nishantm/

  Datopotamab deruxtecan-dlnk is approved by the USFDA for unresectable or metastatic, HR-positive, HER2-negative breast cancer
• Nishant Mittal (PhD)

  https://cancerfax.com/author/nishantm/

  Remestemcel-L-rknd is approved by the USFDA for steroid-refractory acute graft versus host disease in pediatric patients